Acta Haematologica最新文献

{"title":"Prognostic Factors and Survival Outcomes in Ovarian Lymphoma: A Population-Based Analysis.","authors":"Pierre Loap, Youlia Kirova","doi":"10.1159/000552294","DOIUrl":"10.1159/000552294","url":null,"abstract":"<p><strong>Introduction: </strong>Primary ovarian lymphoma represents a rare clinical entity accounting for 0.5% of non-Hodgkin lymphomas and 1.5% of ovarian neoplasms. Current literature is limited to small case series, with poorly defined prognostic factors and optimal treatment strategies.</p><p><strong>Methods: </strong>This retrospective cohort study utilized the SEER database (2000-2020) to identify patients with ovarian lymphoma. Patients were categorized as localized primary ovarian lymphoma (L-POL, stage I) or lymphoma involving the ovary (LIO, stages II-IV, or unknown). Cox proportional hazards regression identified independent prognostic factors for overall survival (OS) and cancer-specific survival (CSS).</p><p><strong>Results: </strong>A total of 221 patients were identified, representing the largest ovarian lymphoma cohort ever reported. The cohort included 75 L-POL (33.9%) and 146 LIO (66.1%) patients. Median age was 49 years. Diffuse large B-cell lymphoma was the most common histology (62.0%). L-POL patients demonstrated higher proportions of Black patients (13.3% vs. 4.1%, p = 0.022), follicular lymphoma (22.7% vs. 12.3%), and unilateral disease (89.3% vs. 61.6%). At median follow-up of 80 months, 5-year and 10-year CSS rates were 77.7% and 75.3% overall, and 87.4% and 85.5% for L-POL patients. In multivariate analysis, age (HR 1.035, p < 0.001), L-POL (grade I) classification (HR 0.435, p = 0.023), and high-grade histology (HR 4.898, p = 0.009) were independent prognostic factors for CSS. Surgery, radiotherapy, and chemotherapy showed no survival benefit in multivariate analysis. Surgery was performed in 86.9% of patients, with 9.9% undergoing inappropriate debulking procedures.</p><p><strong>Conclusions: </strong>L-POL represents a distinct clinical presentation with excellent long-term prognosis. Age, L-POL classification, and histological grade are independent prognostic factors. The high rate of inappropriate surgical procedures, ranging from hysterectomy and debulking to pelvic exenteration, underscores the critical need for improved preoperative recognition. Optimal management should emphasize limited surgical intervention for diagnosis and fertility preservation, followed by systemic chemotherapy tailored to lymphoma subtype and stage.</p>","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-9"},"PeriodicalIF":2.8,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13331460/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147809127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Persistent Splenomegaly Is Associated with Morbidity in Tanzanian Children with Sickle Cell Anemia: Secondary Analysis of the SPHERE Trial.","authors":"Emmanuela E Ambrose, George Tomlinson, Patrick S Ngoya, Susan E Stuber, Teresa S Latham, Russell E Ware, Abel N Makubi, Luke R Smart","doi":"10.1159/000552026","DOIUrl":"10.1159/000552026","url":null,"abstract":"<p><strong>Introduction: </strong>African children with sickle cell anemia (SCA) often have splenomegaly with recurrent cytopenias that complicate management, rather than the splenic atrophy typically observed in SCA.</p><p><strong>Methods: </strong>We analyzed the presence, persistence, and impact of splenomegaly in the Stroke Prevention with Hydroxyurea Enabled through Research and Education (SPHERE) trial (NCT03948867), an open-label trial of dose-escalated hydroxyurea to prevent stroke in Tanzanian children with SCA. Palpable splenomegaly was recorded at each visit. Annual ultrasound measurements were compared to age- and height-related references. Longitudinally, palpable splenomegaly was categorized as infrequent (present in <5% visits), intermittent (10-50% visits), or persistent (>50% visits). Adverse events (AEs) and hydroxyurea dose-limiting toxicities (DLTs) were compared using incidence rate ratios (IRRs) among the three categories.</p><p><strong>Results: </strong>At enrollment, splenomegaly was identified in 48/196 (25%) by palpation and 78 (40%) by ultrasound. Across 221 patient-years of treatment in 53 children, splenomegaly was intermittent in 19% and persistent in 21%. At 12 months, children with persistent splenomegaly were compared to those with infrequent splenomegaly and had achieved similar hydroxyurea dose (23.1 vs. 27.6 mg/kg/day, p = 0.136), hemoglobin (9.0 vs. 9.1 g/dL, p = 0.877), and HbF (23.8 vs. 24.3%, p = 0.481), but experienced more vaso-occlusive AE (IRR = 3.8, p value 0.122), transfusions (IRR = 7.1, p value 0.014), and DLTs (IRR = 3.2, p value 0.073).</p><p><strong>Conclusion: </strong>Splenomegaly is common in Tanzanian children with SCA, often persistent, worsens clinical outcomes, and complicates hydroxyurea. Its cause remains unclear, and further investigation is urgently needed to clarify its etiology, improve its management, and ensure optimal hydroxyurea treatment.</p>","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-11"},"PeriodicalIF":2.8,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13182776/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147759518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Venetoclax-Based Regimens in Chronic Myelomonocytic Leukemia: A Systematic Review and Meta-Analysis.","authors":"Mohammed Abdulgayoom, Mohammad S Afana, Leen Haj Saleh, Aadhila Abbas Manthiri, Noor A Aweer, Mohammad Bakheet, Abdulrahman F Al-Mashdali, Shehab F Mohamed","doi":"10.1159/000551885","DOIUrl":"10.1159/000551885","url":null,"abstract":"<p><strong>Introduction: </strong>Chronic myelomonocytic leukemia (CMML) is a biologically heterogeneous myelodysplastic/myeloproliferative neoplasm with limited disease-modifying treatment options beyond hypomethylating agents (HMAs) and allogeneic hematopoietic stem cell transplantation. Venetoclax, a selective BCL-2 inhibitor, is increasingly used off-label in CMML, but its CMML-specific efficacy and safety remain incompletely defined.</p><p><strong>Methods: </strong>We conducted a systematic review and meta-analysis in accordance with PRISMA 2020. Eligible studies included adult patients with CMML treated with venetoclax-based regimens and reporting extractable CMML-specific outcomes. PubMed, Embase, Cochrane CENTRAL, conference proceedings, and trial registries were searched through August 2025. Random-effects meta-analyses of proportions were performed for complete remission (CR), marrow complete remission (mCR), and overall response rate (ORR).</p><p><strong>Results: </strong>Seventeen publications representing nine unique studies were included, comprising 145 venetoclax-treated CMML patients. Most regimens combined venetoclax with azacitidine, decitabine, or oral decitabine-cedazuridine, with heterogeneous dosing schedules and frequent CYP3A-guided dose modifications. Responses typically occurred early, within one to two treatment cycles, but durability was generally modest. The pooled CR rate was 19.1% (95% CI: 9.4-34.9; I2 = 55%), the pooled mCR rate was 36.4% (95% CI: 24.7-50.0; I2 = 21%), and the pooled ORR was 71.9% (95% CI: 56.5-83.4; I2 = 56%). Venetoclax-based therapy was associated with substantial myelosuppression, including frequent grade ≥3 neutropenia and thrombocytopenia, with clinically relevant infectious complications. Early mortality was low in studies reporting short-term outcomes.</p><p><strong>Conclusion: </strong>Venetoclax-based regimens demonstrate measurable but limited activity in CMML, with high overall response rates but low CR rates and modest durability. Prospective CMML-specific trials are needed to define optimal dosing, clarify comparative effectiveness, and identify patients most likely to benefit.</p>","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-16"},"PeriodicalIF":2.8,"publicationDate":"2026-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13268615/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147632176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case Report of Tyrosine Kinase Inhibitor Interruption in a Patient with Multilineage Philadelphia-Positive Acute Lymphoblastic Leukemia.","authors":"Hannah Goulart, Julie Braish, Nicholas J Short, Nitin Jain, Koji Sasaki, Hagop Kantarjian, Elias J Jabbour","doi":"10.1159/000551699","DOIUrl":"10.1159/000551699","url":null,"abstract":"<p><strong>Introduction: </strong>Measurable residual disease (MRD) assessment in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) commonly relies on reverse transcription polymerase chain reaction detection of BCR::ABL1 transcripts. However, discordance between BCR::ABL1 PCR and next-generation sequencing (NGS)-based MRD assays targeting immunoglobulin/T-cell receptor (IG/TR) rearrangements may occur, particularly in cases of multilineage Ph+ ALL, complicating treatment decisions such as tyrosine kinase inhibitor (TKI) discontinuation.</p><p><strong>Case presentation: </strong>We report a 54-year-old female with Ph+ ALL who achieved durable remission with sustained NGS MRD negativity by IG/TR despite persistent low-level BCR::ABL1 transcript positivity. Following self-discontinuation of ponatinib, she experienced a rapid rise in BCR::ABL1 transcripts and loss of cytogenetic remission in myeloid cells, while remaining morphologically in remission and NGS MRD-negative. Reintroduction of ponatinib resulted in a prompt transcript decline.</p><p><strong>Conclusion: </strong>This case highlights the clinical significance of multilineage Ph+ ALL and its distinct biological background, thereby underscoring caution with TKI discontinuation despite deep NGS MRD negativity and may support continued TKI therapy in this setting.</p>","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-6"},"PeriodicalIF":1.1,"publicationDate":"2026-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147589256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Complex Case of Anti-e Mimicking Autoantibody Development Leading to Warm Autoimmune Hemolytic Anemia: Case Report.","authors":"Ilsa Hale, Kristina L Kunes, Jean Sabile, Jacob Dougherty, Trisha Wong, Michael Heinrich","doi":"10.1159/000550486","DOIUrl":"10.1159/000550486","url":null,"abstract":"<p><strong>Introduction: </strong>Newly diagnosed autoimmune hemolytic anemia (AIHA) develops in 1-3 individuals per 100,000 people per year. Warm autoimmune hemolytic anemia (WAIHA) is the most common type of AIHA, accounting for approximately 70-80% of cases. This report outlines a complex presentation of DAT-negative, anti-e-mimicking autoantibody mediated WAIHA following a transient viral infection in an adult male patient with no prior transfusions.</p><p><strong>Case presentation: </strong>The 55-year-old male patient presented with several weeks of flu-like symptoms followed by jaundice, dyspnea, and progressive fatigue. Initial laboratory workup revealed hemolytic anemia, and subsequent serologic testing identified a warm autoantibody with anti-C specificity, but was ultimately consistent with an anti-e mediated WAIHA.</p><p><strong>Conclusion: </strong>This report highlights a complex case of a patient with an autoantibody mimicking anti-e associated WAIHA and the challenge of identifying suitable transfusion options.</p>","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-6"},"PeriodicalIF":2.8,"publicationDate":"2026-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13584614/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147455089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic Myeloid Leukemia: Historical Perspective, Pathophysiology, and Treatment Advances.","authors":"Songphol Tungjitviboonkun, Lea Daran, Sorrawit Unsuwan","doi":"10.1159/000551493","DOIUrl":"10.1159/000551493","url":null,"abstract":"<p><strong>Background: </strong>Chronic myeloid leukemia (CML) was the first leukemia to be described and remains one of the most well-studied hematologic malignancies. Since its initial description in 1845, CML has evolved from a fatal hematologic disease into a manageable chronic condition.</p><p><strong>Summary: </strong>This review traces the historical evolution of CML research, from its first clinical recognition in the mid-19th century to modern molecular diagnostics and targeted therapy. Key milestones include the discovery of the Philadelphia chromosome in 1960, identification of the BCR::ABL1 fusion gene in the 1980s, and the subsequent development of tyrosine kinase inhibitors (TKIs). The introduction of imatinib in the early 2000s revolutionized CML treatment, transforming a fatal disease into a chronic condition with near-normal life expectancy for most patients. Second- and third-generation TKIs have since been introduced to overcome drug resistance and target specific BCR::ABL1 mutations, such as T315I. Recently, research has focused on mechanisms of TKI resistance, novel signaling pathways, and strategies to achieve treatment-free remission (TFR). Emerging therapies such as vamotinib, KF1601, and combination regimens are being explored. Furthermore, new insights into non-kinase functions of BCR::ABL1 and the role of microRNAs in resistance open additional therapeutic avenues.</p><p><strong>Key messages: </strong>CML remains the most successful example of how understanding molecular pathogenesis can directly translate into targeted therapy. Strategic shifts toward multi-generational TKIs and combination regimens are essential to address the challenges posed by clonal evolution and TKI resistance. Modern clinical goals have shifted to sustained TFR, aiming to transform CML from a chronic to a curable condition.</p>","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-16"},"PeriodicalIF":2.8,"publicationDate":"2026-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13186551/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147455106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differentiation Therapy in Acute Myeloid Leukemia: Advances in Phenotypic Screening and CRISPR-Based Functional Genomics.","authors":"Shinichiro Takahashi","doi":"10.1159/000551445","DOIUrl":"10.1159/000551445","url":null,"abstract":"<p><strong>Background: </strong>Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous malignancy characterized by a differentiation block in myeloid progenitors. Although advances in molecular targeted therapies have improved outcomes in selected subgroups, long-term prognosis remains poor for many patients. Differentiation therapy, exemplified by the success of all-trans retinoic acid in acute promyelocytic leukemia (APL), represents an alternative therapeutic paradigm that aims to overcome the differentiation blockade rather than directly inducing cytotoxicity.</p><p><strong>Summary: </strong>This review summarizes recent advances in phenotypic screening and CRISPR-based functional genomics that have contributed to the discovery of novel differentiation-inducing strategies in AML. High-throughput phenotypic screening approaches using compound libraries, computational tools, and integrative transcriptomic analyses have identified several candidate differentiation inducers. For example, triciribine, an AKT inhibitor, has been identified as a differentiation-inducing compound in AML models. In parallel, CRISPR loss- and gain-of-function screens have uncovered multilayered regulatory networks governing AML differentiation, including transcriptional regulators (e.g., KAT6A), metabolic dependencies (e.g., NMNAT1, glucose transporter type 1), and post-transcriptional regulators (e.g., ZFP36L2, YTHDC1). Emerging computational approaches, such as the Lineage Maturation Index and single-cell data integration, further enhance target prioritization and improve the translational relevance of screening results. Despite these advances, differentiation therapy outside APL remains challenging due to partial maturation, context-dependent responses, and AML heterogeneity.</p><p><strong>Key messages: </strong>Recent advances in phenotypic screening and CRISPR-based functional genomics have expanded our understanding of the molecular mechanisms governing AML differentiation and have revealed novel therapeutic vulnerabilities. Integration of these discovery platforms with computational and single-cell approaches may facilitate the development of differentiation-based strategies for a broader spectrum of AML patients.</p>","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-22"},"PeriodicalIF":1.1,"publicationDate":"2026-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147455118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reconsidering Asparaginase in Leukemia Therapy.","authors":"Maria Frost, Vivek Subbiah, Branko Cuglievan, Miriam B Garcia","doi":"10.1159/000551486","DOIUrl":"10.1159/000551486","url":null,"abstract":"","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-3"},"PeriodicalIF":1.1,"publicationDate":"2026-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147455150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Pregnancy-Associated Aplastic Anemia.","authors":"Xinxin Li, Liangliang Wu, Yumiao Li, Wenjian Mo, Xiaowei Chen, Ming Zhou, Ruiqing Zhou, Shilin Xu, Shiyi Pan, Caixia Wang, Shunqing Wang, Yuping Zhang","doi":"10.1159/000551296","DOIUrl":"10.1159/000551296","url":null,"abstract":"<p><strong>Introduction: </strong>The prognosis and management of pregnancy-associated aplastic anemia (PAA) following allogeneic hematopoietic stem cell transplantation (allo-HSCT) remain uncertain. This retrospective study was conducted to describe our clinical experience and to explore the efficacy and safety of allo-HSCT in patients with PAA.</p><p><strong>Methods: </strong>A retrospective observational study was evaluated the safety and feasibility of allo-HSCT in 18 patients with PAA who were treated between January 2013 and November 2023.</p><p><strong>Results: </strong>Median neutrophil engraftment occurred at 11.5 days (range: 6-15), and platelet engraftment occurred at 11.5 days (range: 7-28). The cumulative incidence (CuI) of both neutrophil and platelet engraftment was 100%. The CuI rates were 22.96% (95% CI, 13.68-27.32) for grade II acute graft-versus-host disease (aGVHD) and 12.61% (95% CI, 9.32-29.28) for chronic GVHD (cGVHD). No cases of grade III-IV aGVHD, extensive cGVHD, or relapse were observed. The CuI of transplantation-related mortality was 19.87% (95% CI, 13.15-30.73). Among the 15 surviving patients, the median follow-up was 47.0 months (range: 7.6-122.2 months). The overall survival and relapse/rejection-free rates were both 80.14% (95% CI, 69.27-86.86).</p><p><strong>Conclusion: </strong>These findings suggest that allo-HSCT is a viable and effective treatment option for PAA. The donor types included 8 matched sibling donors, 1 matched unrelated donor, 3 mismatched unrelated donors, and 6 haploidentical donors.</p>","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-14"},"PeriodicalIF":1.1,"publicationDate":"2026-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147455129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BEAC Induction Regimen and Prior Thoracic Radiotherapy Increases the Risk of ASCT-Associated Pneumonitis.","authors":"Elina Kaprio, Anna Jokimäki, Hanne Kuitunen, Joel Kontiainen, Tuomas Selander, Taina Turpeenniemi-Hujanen, Outi Kuittinen","doi":"10.1159/000551311","DOIUrl":"10.1159/000551311","url":null,"abstract":"<p><strong>Introduction: </strong>High-dose chemotherapy (HDT) followed by autologous stem cell transplant (ASCT) has been standard of care in the treatment of relapsed and refractory lymphoma. Some severe toxicities are associated with this treatment modality. Pulmonary toxicity is one of these significant adverse effects and a potential cause of treatment-related mortality.</p><p><strong>Methods: </strong>In this retrospective study, we report the incidence, risk factors, and outcome of treatment-induced pneumonitis in 286 lymphoma patients receiving HDT followed by ASCT.</p><p><strong>Results: </strong>The cumulative incidence of treatment-induced pneumonitis was 4.6% and occurred in 11/286 patients. Three months incidence rate was 2.6%. Most of the patients diagnosed with treatment-induced pneumonitis had received BEAC as HDT regimen. The risk of treatment-induced pneumonitis was higher if HDT-ASCT was given in later treatment lines. Also, a prior thoracic radiotherapy as part of first-line treatment was associated with higher risk for pneumonitis after HDT-ASCT. In 2 patients, the pneumonitis did not respond to high-dose steroid treatment.</p><p><strong>Conclusion: </strong>This study provides new information about the incidence of pneumonitis associated with HDT-ASCT and its risk factors, which might be useful to take into consideration during and after treatment with HDT-ASCT.</p>","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-9"},"PeriodicalIF":2.8,"publicationDate":"2026-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13148807/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147388774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}